Drug Trial Radar · NCT03948347
Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Feb 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,708
Planned (sponsor's estimate)
Start
Jun 25, 2019
Primary completion
Dec 2023
Study completion Jun 2024
Sponsor
- Lead sponsor
- First Affiliated Hospital of Jinan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 13, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of Health stroke scale, NIHSS ≤ 3) or high-risk transient ischemic attack (TIA) (ABCD2 score ≥ 4 ) patients with type 2 diabetes mellitus.
Conditions
- Ischemic Stroke
- Transient Ischemic Attack
- Type 2 Diabetes Mellitus
Interventions
LiraglutideDrug
The treatment arm will receive the starting dose of liraglutide of 0.6 mg/d subcutaneously once daily, and the dose will be increased to 1.8 mg/d in two weeks, and then continue to administrate this dose for 90 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic)Time frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.